Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 22% treatment Improvement Relative Risk ICU admission 59% treatment Mortality, 20ng/mL -8% levels ICU admission, 20ng/mL 5% levels Progression 6% levels Vitamin D for COVID-19  Baykal et al.  LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? Retrospective 75 patients in Turkey (April 2020 - March 2021) Lower ICU admission with vitamin D (p=0.005) c19early.org Baykal et al., J. Health Sciences and .., May 2022 Favors vitamin D Favors control

Correlation of vitamin D level with the clinical-radiological severity of COVID-19 in geriatric patients

Baykal et al., Journal of Health Sciences and Medicine, doi:10.32322/jhsm.1063405
May 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 75 patients in Turkey showing lower ICU admission with vitamin D treatment in unadjusted results subject to confounding by time and indication (treatment was given to patients with low levels and only during a certain period). There was no significant difference in outcomes based on vitamin D levels.
Cholecalciferol was used in this study. Meta analysis shows that late stage treatment with calcitriol / calcifediol (or paricalcitol, alfacalcidol, etc.) is more effective than cholecalciferol: 65% [41‑79%] lower risk vs. 39% [26‑49%] lower risk. Cholecalciferol requires two hydroxylation steps to become activated - first in the liver to calcifediol, then in the kidney to calcitriol. Calcitriol, paricalcitol, and alfacalcidol are active vitamin D analogs that do not require conversion. This allows them to have more rapid onset of action compared to cholecalciferol. The time delay for cholecalciferol to increase serum calcifediol levels can be 2-3 days, and the delay for converting calcifediol to active calcitriol can be up to 7 days.
This is the 83rd of 120 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 248 sextillion).
29 studies are RCTs, which show efficacy with p=0.0000024.
risk of death, 22.2% lower, RR 0.78, p = 0.43, treatment 7 of 18 (38.9%), control 28 of 56 (50.0%), NNT 9.0, excluded in exclusion analyses: unadjusted results with no group details; significant confounding by time possible due to separation of groups in different time periods.
risk of ICU admission, 59.4% lower, RR 0.41, p = 0.005, treatment 5 of 18 (27.8%), control 39 of 57 (68.4%), NNT 2.5, excluded in exclusion analyses: unadjusted results with no group details; significant confounding by time possible due to separation of groups in different time periods.
risk of death, 8.0% higher, RR 1.08, p = 0.80, high D levels (≥20ng/mL) 11 of 20 (55.0%), low D levels (<20ng/mL) 28 of 55 (50.9%), outcome based on serum levels.
risk of ICU admission, 4.8% lower, RR 0.95, p = 1.00, high D levels (≥20ng/mL) 9 of 20 (45.0%), low D levels (<20ng/mL) 26 of 55 (47.3%), NNT 44, outcome based on serum levels.
risk of progression, 6.1% lower, RR 0.94, p = 0.77, high D levels (≥20ng/mL) 14 of 20 (70.0%), low D levels (<20ng/mL) 41 of 55 (74.5%), NNT 22, severe/critical, outcome based on serum levels.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Baykal et al., 30 May 2022, retrospective, Turkey, peer-reviewed, 2 authors, study period 1 April, 2020 - 1 March, 2021, dosage 300,000IU single dose. Contact: drhusnubaykal@hotmail.com.
This PaperVitamin DAll
Correlation of vitamin D level with the clinical-radiological severity of COVID-19 in geriatric patients
Hüsnü Baykal, Ayşe Füsun Ülger
Journal of Health Sciences and Medicine, doi:10.32322/jhsm.1063405
Objective: This study was planned to investigate the effect of 25-OH-Vitamin D (Vit D) deficiency on clinical and radiological findings of coronavirus disease-2019 (COVID-19) in geriatric patients hospitalized due to COVID-19. Material and Method: Seventy-five patients who were treated for COVID-19 were reviewed retrospectively, and grouped in relation with their ages [(1) 65-74, (2) 75-84, (3) >84 years] and the severity of Vit D deficiency [(1) severe deficiency: <10 ng/ mL, (2) moderate deficiency: 10-20 ng/mL, (3) minor deficiency: 21-30 ng/mL, (4) normal: >30 ng/mL]. The complaints on admission, comorbidities, intensive care unit (ICU) need, length of hospital stay, laboratory data, and mortality of the ones who had and did not have Vit D replacement (n=18/75) were recorded. The patients were analyzed for COVID-19 severity using radiological and clinical markers. Results: Moderate Vit D deficiency (10-20 ng/mL) was frequently detected. When the disease severity and Vit D levels were analyzed, it was found that the disease was more severe (46.6%) in the Vit D <10 ng/ml group, and milder (37.5%) in the >30 ng/ml group, but there was no statistically significant difference among the groups. Low or high Vit D levels did not show any significant correlations with the severity of pneumonia or the thorax CT findings. The intensive care unit (ICU) admission rate was significantly lower in those who had Vit D replacement (p<0.001). Conclusion: The ICU admission rate was lower in patients who had Vit D replacement, however, serum Vit D concentrations were not correlated with COVID-19 severity or mortality risk.
References
Annweiler, Corvaisier, Gautier, Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: The GERIA-COVID quasiexperimental study, Nutrients
Baktash, Hosack, Patel, Vitamin D status and outcomes for hospitalized older patients with COVID-19, Postgrad Med J
Bassatne, Basbous, Chakhtoura, El Zein, Rahme et al., The link between COVID-19 and Vitamin D (VIVID): a systematic review and meta-analysis, Metabolism
Bertoldi, Gianesello, Calò, Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVID-19, Aliment Pharmacol Ther
Bulut, Karamanlı, Şahin, Çelik, Biber, Association between vitamin D levels and frequency of disease exacerbations and hospitalizations in patients with COPD, J Health Sci Med
Cereda, Bogliolo, Klersy, Lobascio, Masi et al., Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital, Clin Nutr
Cheng, Du, Hong, Factors associated to serum 25-hydroxyvitamin D levels among older adult populations in urban and suburban communities in Shanghai, China, BMC Geriatr
Daneshkhah, Agrawal, Eshein, Subramanian, Roy et al., Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients, Aging Clin Exp Res
Ebadi, Montano-Loza, Perspective: improving vitamin D status in the management of COVID-19, Eur J Clin Nutr
Glinsky, Tripartite combination of candidate pandemic mitigation agents: vitamin D, Quercetin, and Estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells, Biomedicines
Grant, Lahore, Mcdonnell, Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths, Nutrients
Hanley, Cranney, Jones, Guidelines committee of the scientific advisory council of osteoporosis Canada. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada, CMAJ
Hastie, Mackay, Ho, Vitamin D concentrations and COVID-19 infection in UK Biobank, Diabetes Metab Syndr
Hastie, Pell, Sattar, Vitamin D and COVID-19 infection and mortality in UK Biobank, Eur J Nutr
Hernandez, Nan, Fernandez-Ayala, Garcia-Unzueta, Hernandez-Hernandez et al., Vitamin D status in hospitalized patients with SARS-CoV-2 infection, J Clin Endocrinol Metab
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Ilie, Stefanescu, Smith, The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality, Aging Clin Exp Res
Im, Je, Baek, Chung, Kwon et al., Nutritional status of patients with COVID-19, Int J Infect Dis
Jain, Chaurasia, Sengar, Singh, Mahor et al., Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers, Sci Rep
Kweder, Eidi, Vitamin D deficiency in elderly: Risk factors and drugs impact on vitamin D status, Avicenna J Med
Maghbooli, Sahraian, Ebrahimi, Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection, PLoS One
Murai, Fernandes, Sales, Pinto, Goessler et al., Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial, JAMA
Ohaegbulam, Swalih, Patel, Smith, Perrin, Vitamin D supplementation in COVID-19 patients: a clinical case series, Am J Ther
Oscanoa, Amado, Vidal, Laird, Ghashut et al., The relationship between the severity and mortality of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration-a metaanalysis, Adv Respir Med
Panagiotou, Tee, Ihsan, Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity, Clin Endocrinol (Oxf)
Rhodes, Subramanian, Laird, Griffin, Kenny, Perspective: Vitamin D deficiency and COVID-19 severityplausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis, J Intern Med
Sassi, Tamone, Amelio, Vitamin D: nutrient, hormone, and immunomodulator, Nutrients
Shah, Saxena, Mavalankar, Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis, QJM
Simpson, Kay, Abbara, Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA-Secondary Publication, J Thorac Imaging
Sloka, Silva, Wang, Yong, Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism, J Neuroinflammation
Smet, Smet, Herroelen, Gryspeerdt, Martens, Serum 25(OH)D level on hospital admission associated with COVID-19 stage and mortality, Am J Clin Pathol
Sulli, Gotelli, Casabella, Vitamin D and lung outcomes in elderly COVID-19 patients, Nutrients
Tan, Ho, Kalimuddin, Cherng, Teh et al., A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients, medRxiv
Wyskida, Wieczorowska-Tobis, Chudek, Prevalence and factors promoting the occurrence of vitamin D deficiency in the elderly, Postepy Hig Med Dosw (Online
Yildiz, Senel, Kavurgaci, Ozturk, Ozturk, The prognostic significance of vitamin D deficiency in patients with COVID-19 pneumonia, Bratisl Lek Listy
Zhao, Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies, Int J Antimicrob Agents
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit